N-acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids - From fishy endocannabinoids to potential leads

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 772-783

  Meijerink, Jocelijn ^a   Balvers, Michiel ^a   Witkamp, Renger ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

endocannabinoid system; fish oil; n 3; PUFA, DHA, EPA

Indexed keywords

AMINE; ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID DOPAMINE CONJUGATE; DOCOSAHEXAENOIC ACID SEROTONIN CONJUGATE; DOPAMINE; ENDOCANNABINOID; ETHANOLAMINE; FISH OIL; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID DOPAMINE CONJUGATE; LINOLENIC ACID; NEUROTRANSMITTER; OLEIC ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SEROTONIN; STEARIC ACID; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROTECTION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENERGY BALANCE; FOOD INTAKE; HUMAN; IMMUNOMODULATION; INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

ACYLATION; ALPHA-LINOLENIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CANNABINOID RECEPTOR AGONISTS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOPAMINE; DRUG DELIVERY SYSTEMS; EICOSAPENTAENOIC ACID; ENDOCANNABINOIDS; ETHANOLAMINE; FATTY ACIDS, OMEGA-3; FISH OILS; FISHES; HUMANS; NEUROPROTECTIVE AGENTS; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; SEAFOOD;

EID: 84878313223     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12030     Document Type: Article

References (81)

1. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, et al. (1995). Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 273: 1172-1181.
2. Alexander SPH, Kendall DA, (2007). The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152: 602-623.
3. Alexander SPH, Mathie, A,., Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br. J. Pharmacol 164 (Suppl. 1): S1-S324.
4. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, et al. (2008). Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781: 200-212.
5. Balvers MGJ, Verhoeckx KCM, Plastina P, Wortelboer HM, Meijerink J, Witkamp RF, (2010). Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties. Biochim Biophys Acta 1801: 1107-1114.
6. Balvers MGJ, Verhoeckx KCM, Bijlsma S, Rubingh CM, Meijerink J, Wortelboer HM, et al. (2012a). Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissues. Metabolomics 8: 1130-1147.
7. Balvers MGJ, Verhoeckx KCM, Meijerink J, Bijlsma S, Rubingh CM, Wortelboer HM, et al. (2012b). Time-dependent effect of in vivo inflammation on eicosanoid and endocannabinoid levels in plasma, liver, ileum and adipose tissue in C57BL/6 mice fed a fish-oil diet. Int Immunopharmacol 13: 204-214.
8. Banni S, Di Marzo V, (2010). Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res 54: 82-92.
9. Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, et al. (2009). Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 139: 1495-1501.
10. Bazan NG, Molina MF, Gordon WC, (2011). Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 31: 321-351.
11. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V, (2001). Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A 98: 6402-6406.
12. Bezuglov V, Bobrov M, Gretskaya N, Gonchar A, Zinchenko G, Melck D, et al. (2001). Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett 11: 447-449.
13. Bisogno T, (2008). Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 20 (Suppl. 1): 1-9.
14. Bisogno T, Delton-Vandenbroucke I, Milone A, Lagarde M, Di Marzo V, (1999). Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys 370: 300-307.
15. Bisogno T, Melck D, Bobrov M, Gretskaya NM, Bezuglov VV, De Petrocellis L, et al. (2000). N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351: 817-824.
16. Bobrov MY, Lyzhin AA, Andrianova EL, Gretskaya NM, Zinchenko GN, Frumkina LE, et al. (2006). Antioxidant and neuroprotective properties of N-docosahexaenoyl dopamine. Bull Exp Biol Med 142: 425-427.
17. Bradshaw HB, Rimmerman N, Hu SSJ, Burstein S, Walker JM, (2009). Chapter 8. Novel endogenous N-acyl glycines: identification and characterization. In:, Gerald L, (ed.). Vitamins & Hormones, Vol. 81. Elsevier-Academic Press: San Diego, CA, pp. 191-205.
18. Brenna JT, Salem N Jr, Sinclair AJ, Cunnane SC, (2009). α-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 80: 85-91.
19. Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, et al. (2010). Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 31: 1584-1591.
20. Brown I, Wahle KWJ, Cascio MG, Smoum-Jaouni R, Mechoulam R, Pertwee RG, et al. (2011). Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 85: 305-310.
21. Burstein S, Zurier R, (2009). Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 11: 109-119.
22. Calder PC, (2009). Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 91: 791-795.
23. Calder PC, (2011). Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 668 (Suppl. 1): S50-S58.
24. Carlson SE, (2009). Docosahexaenoic acid supplementation in pregnancy and lactation. Am J Clin Nutr 89: 678S-6684.
25. Connor M, Vaughan CW, Vandenberg RJ, (2010). N-Acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol 160: 1857-1871.
26. Dainese E, Sabatucci A, Angelucci CB, Barsacchi D, Chiarini M, MacCarrone M, (2012). Impact of embedded endocannabinoids and their oxygenation by lipoxygenase on membrane properties. ACS Chem Neurosci 3: 386-392.
27. Dang HT, Kang GJ, Yoo ES, Hong J, Choi JS, Kim HS, et al. (2011). Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads. Bioorg Med Chem 19: 1520-1527.
28. De Caterina R, (2011). n-3 fatty acids in cardiovascular disease. N Engl J Med 364: 2439-2450.
29. Di Marzo V, Bisogno T, De Petrocellis L, (2007). Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 14: 741-756.
30. Ezzili C, Otrubova K, Boger DL, (2010). Fatty acid amide signaling molecules. Bioorg Med Chem Lett 20: 5959-5968.
31. Farrell EK, Merkler DJ, (2008). Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov Today 13: 558-568.
32. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA, (1993). Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A 90: 7656-7660.
33. Fowler CJ, (2012). Anandamide uptake explained? Trends Pharmacol Sci 33: 181-185.
34. Hansen HS, Artmann A, (2008). Endocannabinoids and nutrition. J Neuroendocrinol 20 (Suppl. 1): 94-99.
35. Hansen HS, Diep TA, (2009). N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 78: 553-560.
36. Kaczocha M, Glaser ST, Deutsch DG, (2009). Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci U S A 106: 6375-6380.
37. Kaczocha M, Vivieca S, Sun J, Glaser ST, Deutsch DG, (2012). Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J Biol Chem 287: 3415-3424.
38. Kim HY, Moon HS, Cao D, Lee J, Kevala K, Jun SB, et al. (2011b). N-docosahexaenoylethanolamide promotes development of hippocampal neurons. Biochem J 435: 327-336.
39. Kim H-Y, Spector AA, (2012). Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. Prostaglandins Leukot Essent Fatty Acids. http://dx.doi.org/10.1016/j.plefa.2012.08.002 (in press).
40. Kim H-Y, Spector AA, Xiong Z-M, (2011a). A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. Prostaglandins Other Lipid Mediat 96: 114-120.
41. Lafourcade M, Larrieu T, Mato S, Duffaud A, Sepers M, Matias I, et al. (2011). Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci 14: 345-350.
42. Lucanic M, Held JM, Vantipalli MC, Klang IM, Graham JB, Gibson BW, et al. (2011). N-acylethanolamine signalling mediates the effect of diet on lifespan in Caenorhabditis elegans. Nature 473: 226-229.
43. Maccarrone M, Dainese E, Oddi S, (2010a). Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 35: 601-608.
44. Maccarrone M, Gasperi V, Catani MV, Diep TA, Dainese E, Hansen HS, et al. (2010b). The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr 30: 423-440.
45. Maione S, De Petrocellis L, De Novellis V, Moriello AS, Petrosino S, Palazzo E, et al. (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150: 766-781.
46. Mayurasakorn KA, Williams JJA, Ten VSB, Deckelbaum RJAB, (2011). Docosahexaenoic acid: brain accretion and roles in neuroprotection after brain hypoxia and ischemia. Curr Opin Clin Nutr Metab Care 14: 158-167.
47. Meijerink J, Plastina P, Vincken J-P, Poland M, Attya M, Balvers M, et al. (2011). The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new link between fish oil and inflammation. Br J Nutr 105: 1798-1807.
48. Movahed P, Jonsson BA, Birnir B, Wingstrand JA, Jorgensen TD, Ermund A, (2005). Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem 280: 38496-38504.
49. Mozaffarian D, Wu JHY, (2011). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58: 2047-2067.
50. Muccioli GG, (2010). Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 15: 474-483.
51. Novak EM, Dyer RA, Innis SM, (2008). High dietary ω-6 fatty acids contribute to reduced docosahexaenoic acid in the developing brain and inhibit secondary neurite growth. Brain Res 1237: 136-145.
52. de Novellis V, Palazzo E, Rossi F, De Petrocellis L, Petrosino S, Guida F, et al. (2008). The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 55: 1105-1113.
53. Ortar G, Cascio MG, De Petrocellis L, Morera E, Rossi F, Schiano-Moriello A, et al. (2007). New N-arachidonoylserotonin analogues with potential 'dual' mechanism of action against pain. J Med Chem 50: 6554-6569.
54. Ostroumova TV, Markova LN, Akimov MG, Gretskaya NM, Bezuglov VV, (2010). Docosahexaenoyl dopamine in freshwater hydra: effects on regeneration and metabolic changes. Russ J Dev Biol 41: 164-167.
55. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P, (2009). Endocannabinoids and immune regulation. Pharmacol Res 60: 85-92.
56. Parker G, Gibson NA, Brotchie H, Heruc G, Rees A-M, Hadzi-Pavlovic D, (2006). Omega-3 fatty acids and mood disorders. Am J Psychiatry 163: 969-978.
57. Pillarisetti S, Alexander CW, Khanna I, (2009). Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases. Drug Discov Today 14: 1098-1111.
58. Rapoport SI, Ramadan E, Basselin M, (2011). Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission. Prostaglandins Other Lipid Mediat 96: 109-113.
59. Riediger ND, Othman RA, Suh M, Moghadasian MH, (2009). A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc 109: 668-679.
60. de Roos B, Yiannis M, Ingeborg AB, (2009). Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol 158: 413-428.
61. Rouzer CA, Marnett LJ, (2011). Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 111: 5899-5921.
62. Russo GL, (2009). Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 77: 937-946.
63. Sakharova NY, Markova LN, Smirnov AA, Vikhlyantseva EF, Fialkovskaya LA, Bezuglov VV, (2012). Effect of docosahexaenoyl dopamine on the in vitro development of early mouse embryos. Dokl Biol Sci 442: 38-41.
64. Shashoua VE, Hesse GW, (1996). N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci 58: 1347-1357.
65. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R, (1997). Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 40: 659-667.
66. Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, Yamashita A, et al. (1996). Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Eur J Biochem 240: 53-62.
67. Tan B, O'Dell DK, Yu YW, Monn MF, Hughes HV, Burstein S, et al. (2010). Identification of endogenous acyl amino acids based on a targeted lipidomics approach. J Lipid Res 51: 112-119.
68. Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, et al. (2011). Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase d-dependent and -independent pathways. Biochim Biophys Acta 1811: 565-577.
69. Tur JA, Bibiloni MM, Sureda A, Pons A, (2012). Dietary sources of omega 3 fatty acids: public health risks and benefits. Br J Nutr 107 (Suppl. 2): S23-S52.
70. Ueda N, Tsuboi K, Uyama T, (2010a). Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801: 1274-1285.
71. Ueda N, Tsuboi K, Uyama T, (2010b). N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res 49: 299-315.
72. Vandevoorde S, Lambert DM, (2007). The multiple pathways of endocannabinoid metabolism: a zoom out. Chem Biodivers 4: 1858-1881.
73. Verhoeckx KCM, Voortman T, Balvers MGJ, Hendriks HFJ, Mwortelboer H, Witkamp RF, (2011). Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. Biochim Biophys Acta 1811: 578-586.
74. Wallin A, Di Giuseppe D, Orsini N, Patel PS, Forouhi NG, Wolk A, (2012). Fish consumption, dietary long-chain n-3 fatty acids, and risk of type 2 diabetes. Diabetes Care 35: 918-929.
75. Watanabe S, Doshi M, Hamazaki T, (2003). n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69: 51-59.
76. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF, (2006). A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 281: 36569-36578.
77. Wood JT, Williams JS, Pandarinathan L, Janero DR, Lammi-Keefe CJ, Makriyannis A, (2010). Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res 51: 1416-1423.
78. Woodward DF, Carling RWC, Cornell CL, Fliri HG, Martos JL, Pettit SN, et al. (2008). The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther 120: 71-80.
79. Xun P, He K, (2012). Fish consumption and incidence of diabetes. Diabetes Care 35: 930-938.
80. Yang R, Fredman G, Krishnamoorthy S, Agrawal N, Irimia D, Piomelli D, et al. (2011). Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J Biol Chem 286: 31532-31541.
81. Yehuda S, (2002). Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine: a new molecule. Pharmacol Biochem Behav 72: 7-11.